Skip to main content

Table 2 Characterisation of cardiotoxicity in breast cancer patients during or after chemotherapy for each of the reviewed studies

From: A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

  Reference [28] [29] [30] [31] [32] [33] [34] [35]
Cohort size 45 179 363 56 56/32 34 40 72
Treatment regime NAC ECD ECD DOX EPI/DOX DOX AC ECD-T
Assessment of Cardiotoxicity Heart failure 1a 1 0 0 0/0 0 0 0
Acute coronary syndrome 0 0 0 0 0/0 0 0 1
Fatal arrhythmias 0 9 0 0 0/0 0 0 0
Decline of LVEF ≥10% of baseline or below 53% 17 9 19 10 0/0 4 20 12
Elevated Troponin level 0 0 0 0 12/18 0 0 0
  1. Key: EC-D = Epirubicin + Cyclophosphamide (4 cycles) followed by Docetaxel (4 cycles), DOX = Doxorubicin, EPI = Epirubicin, NAC = Cyclophosphamide + Epirubicin (4 cycles) followed by Paclitaxel (9 to 12 weeks), AC = Anthracycline chemotherapy (not specified), LVEF = Left ventricular ejection fraction
  2. aone patient was diagnosed with heart failure after the study period